← Leaderboards
Russell R Broaddus
University Of Tx Md Anderson Can Ctr
$6,374,452
Attributed
$6,379,452
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2008–20$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$17,957,768 · 11
By mechanism
P50$17,947,768 · 10
R13$10,000 · 1
Top collaborators
- Karen Hsieh Lu11 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Rugang Zhang$23,913,209
- Shiaw-Yih Lin$9,839,199
- Melinda S. Yates$1,868,494
- Meera Nanjundan$2,006,869
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorSamplingUterine CancerBaseEndometrial CarcinomaRecurrenceGynecologicResearch Project GrantsCancer CenterProgramsEvaluationSpecimenTranslational ResearchResearch PersonnelResourcesMolecularWomanObesityOperative Surgical ProceduresPathologyTissuesBiological MarkersClinical TrialsHysterectomy
Grant awards (49)
MD Anderson Gynecologic SPORE for Uterine Cancers$1,986,436
P50 · FY2020 · CA
P2: CTNNB1 Mutation and Wnt Pathway Activation Define Clinically Aggressive Endometrioid Endometrial Carcinoma$302,814
P50 · FY2020 · CA · contact PI
MD Anderson Gynecologic SPORE for Uterine Cancers$214,963
P50 · FY2020 · CA
P2: CTNNB1 Mutation and Wnt Pathway Activation Define Clinically Aggressive Endometrioid Endometrial Carcinoma$210,956
P50 · FY2020 · CA · contact PI
Pathology Core$194,116
P50 · FY2020 · CA · contact PI
Evaluation of siRNA nanoformulations and aerosol delivery for treatment of SARS-CoV-2$162,000
P50 · FY2020 · CA
Developmental Research Program$155,291
P50 · FY2020 · CA · contact PI
MD Anderson Gynecologic SPORE for Uterine Cancers$10,000
P50 · FY2020 · CA
P2: CTNNB1 Mutation and Wnt Pathway Activation Define Clinically Aggressive Endometrioid Endometrial Carcinoma$10,000
P50 · FY2020 · CA · contact PI
MD Anderson Gynecologic SPORE for Uterine Cancers$2,090,228
P50 · FY2019 · CA
P2: CTNNB1 Mutation and Wnt Pathway Activation Define Clinically Aggressive Endometrioid Endometrial Carcinoma$290,152
P50 · FY2019 · CA · contact PI
Pathology Core$186,000
P50 · FY2019 · CA · contact PI
Developmental Research Program$148,798
P50 · FY2019 · CA · contact PI
MD Anderson Gynecologic SPORE for Uterine Cancers$2,268,692
P50 · FY2018 · CA
P2: CTNNB1 Mutation and Wnt Pathway Activation Define Clinically Aggressive Endometrioid Endometrial Carcinoma$291,693
P50 · FY2018 · CA · contact PI
Core 1: Pathology Core$231,014
P50 · FY2018 · CA · contact PI
MD Anderson Gynecologic SPORE for Uterine Cancers$192,000
P50 · FY2018 · CA
Pathology Core$179,697
P50 · FY2018 · CA · contact PI
Molecular Modifiers of Endometrial Endometrioid Adenocarcinoma Immune Microenvironment: Impact of PTEN loss and CD73-Generated Adenosine Loss$171,701
P50 · FY2018 · CA · contact PI
Pathology Core$17,455
P50 · FY2018 · CA · contact PI
Molecular Modifiers of Endometrial Endometrioid Adenocarcinoma Immune Microenvironment: Impact of PTEN loss and CD73-Generated Adenosine Loss$17,454
P50 · FY2018 · CA · contact PI
P2: CTNNB1 Mutation and Wnt Pathway Activation Define Clinically Aggressive Endometrioid Endometrial Carcinoma$17,454
P50 · FY2018 · CA · contact PI
MD Anderson Gynecologic SPORE for Uterine Cancers$2,299,997
P50 · FY2017 · CA
P2: CTNNB1 Mutation and Wnt Pathway Activation Define Clinically Aggressive Endometrioid Endometrial Carcinoma$311,991
P50 · FY2017 · CA · contact PI
Core 1: Pathology Core$216,576
P50 · FY2017 · CA · contact PI
Pathology Core$200,000
P50 · FY2017 · CA · contact PI
Molecular Modifiers of Endometrial Endometrioid Adenocarcinoma Immune Microenvironment: Impact of PTEN loss and CD73-Generated Adenosine Loss$192,000
P50 · FY2017 · CA · contact PI
Revision: MD Anderson Gynecologic SPORE for Uterine Cancers$192,000
P50 · FY2017 · CA
MD Anderson Gynecologic SPORE for Uterine Cancers$2,162,000
P50 · FY2016 · CA
P2: CTNNB1 Mutation and Wnt Pathway Activation Define Clinically Aggressive Endometrioid Endometrial Carcinoma$295,325
P50 · FY2016 · CA · contact PI
Pathology Core$189,314
P50 · FY2016 · CA · contact PI
Strategy for the Incorporation of Tissue Biomarkers in the Clinical Management of$174,412
P50 · FY2014 · CA · contact PI
Pathology Core$107,477
P50 · FY2014 · CA · contact PI
Pathology Core$91,360
P50 · FY2014 · CA · contact PI
Strategy for the Incorporation of Tissue Biomarkers in the Clinical Management of$248,412
P50 · FY2013 · CA · contact PI
Pathology Core$172,974
P50 · FY2013 · CA · contact PI
Pathology Core$159,649
P50 · FY2013 · CA · contact PI
Strategy for the Incorporation of Tissue Biomarkers in the Clinical Management of$185,897
P50 · FY2012 · CA · contact PI
Pathology Core$121,897
P50 · FY2012 · CA · contact PI
Pathology Core$97,997
P50 · FY2012 · CA · contact PI
Strategy for the Incorporation of Tissue Biomarkers in the Clinical Management of$202,141
P50 · FY2011 · CA · contact PI
Pathology Core$114,893
P50 · FY2011 · CA · contact PI
Pathology Core$91,622
P50 · FY2011 · CA · contact PI
Strategy for the Incorporation of Tissue Biomarkers in the Clinical Management of$207,334
P50 · FY2010 · CA · contact PI
Pathology Core$117,295
P50 · FY2010 · CA · contact PI
Pathology Core$94,150
P50 · FY2010 · CA · contact PI
Annual Uterine Cancer Biology Symposium$10,000
R13 · FY2010 · CA
Pathology Core$207,660
P50 · FY2009 · CA · contact PI
Pathology Core$144,481
P50 · FY2008 · CA · contact PI